scorecardresearch
Tuesday, April 23, 2024
TopicDCGI

Topic: DCGI

Breakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod

Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.

Calls for caution over phenylephrine’s efficacy, as FDA panel deems decongestant ineffective

Panel report notes that oral phenylephrine is no better than placebo for relieving nasal congestion. In India, phenylephrine is widely used in cough and cold medicines.

Kerala doctors & researchers plan India’s 1st private drug quality assessment drive

Project follows outcry over NMC rule, now on hold, asking medical practitioners to prescribe generics or face penalty. Dr Cyriac Abby Philips or ‘@TheLiverDoc’ part of project.

After WHO alert, drug controller general warns against use of cough syrups containing pholcodine

Pholcodine is used to treat dry cough. WHO had flagged risk of anaphylactic reactions in those who took remedies containing Pholcodine at least 12 months prior to surgery.

‘1st for India’ — device made from pig gall bladder heals skin wounds like burns with few scars

Low-cost tissue-engineering scaffold Cholederm — developed by Thiruvananthapuram-based Sree Chitra Tirunal Institute for Medical Sciences & Technology — approved by DCGI.

All about Serum Institute’s HPV vaccine, India’s 1st indigenous shot against cervical cancer

Pune-based SII has got the go-ahead from the Drugs Controller General of India to market the vaccine. Cervical cancer is one of the leading causes of female cancer mortality worldwide.

DCGI approves Corbevax as first heterologous Covid booster dose for adults

A press release from Corbevax maker said it could be administered as a booster after six months of administration of primary vaccination for restricted use in emergency situation.

DCGI gives nod to Biological E’s Covid vaccine phase 2/3 clinical trials on 5-18 year olds

The trial will be conducted across 10 sites in India. Zydus Cadila's ZyCoV-D is so far the only vaccine to get Emergency Use Authorisation in the 12-18 years age group in India.

Zydus Cadila applies for approval to ZyCov-D, India’s 1st Covid vaccine tested on 12-18-yr-olds

If ZyCov-D gets the approval, it will be the fifth vaccine authorised for use in India after Covishield, Covaxin, Sputnik V and Moderna.

Drug regulator says no need for bridging trials on foreign approved vaccines before India roll out

DCGI modifies earlier order on emergency approval of well-established vaccines, waives several requirements, but retains assessment of first 100 beneficiaries before proper roll out.

On Camera

Pakistan finance minister should learn from Manmohan Singh and engineer an economic revival

Muhammad Aurangzeb has been clamped with more manacles than he has wrists. His immediate task is to negotiate a new loan programme with the IMF.

Economists vs statisticians — the battle being fought over the soul of India’s GDP data

Economists say there are weaknesses in India’s GDP data. But statisticians claim the accusations are based on flawed understanding, saying while GDP has problems, the economists are looking in the wrong places.

‘No brides for Agniveers’: In Rajasthan’s ‘Shaheedon ki nagri’, few takers for defence coaching centres

Coaching centres for Army aspirants in Jhunjhunu are shutting down due to plummeting admissions in the face of a lack of job guarantees under Agnipath Scheme.

These 6 states are key for Modi’s ‘400 paar’ target. They’re also where Opposition can stop him

While this contest looks so predictable in large swathes of our political landscape, it is also more keenly contested than 2019 in some states.